{
    "Clinical Trial ID": "NCT02556632",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I (Curcumin-based Gel)",
        "  Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.",
        "Curcumin-based Gel: Applied topically",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Questionnaire Administration: Ancillary studies",
        "INTERVENTION 2: ",
        "  Arm II (HPR Plus)",
        "  Patients apply HPR Plus\u2122 topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.",
        "  Dermatologic Complications Management: Apply HPR Plus topically",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Questionnaire Administration: Ancillary studies"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Subjects with a diagnosis of non-inflammatory breast cancer or carcinoma in situ",
        "  Subjects must be prescribed and scheduled for \"conventional fractionated\" RT without concurrent chemotherapy; bolus and intensity modulated radiation therapy (IMRT) are permitted; lymph node irradiation (i.e., internal mammary nodes, supraclavicular nodes, axillary nodes, etc) as part of their prescribed radiation therapy are permitted; conventional fractionated radiation therapy regimens eligible for study are described below:",
        "  Minimal (min) total dose: whole breast: 44 gray (Gy); breast boost: 10 Gy; tumor bed = whole breast +/- boost: 50.0 Gy; lymph nodes: 45 Gy",
        "  Maximal (max) total dose: whole breast: 50.4 Gy; breast boost: 20 Gy; tumor bed = whole breast +/- boost: 66.0 Gy; lymph nodes: 50.4 Gy",
        "  Min dose per fraction: whole breast: 1.8 Gy; breast boost: 2.0 Gy; tumor bed = whole breast +/- boost: 1.8 Gy; lymph nodes: 1.8 Gy",
        "  Max dose per fraction: whole breast: 2.0 Gy; breast boost: 2.0 Gy; tumor bed = whole breast +/- boost: 2.0 Gy; lymph nodes: 2.0 Gy",
        "Min # of fractions: whole breast: 22 Gy; breast boost: 5 Gy; tumor bed = whole breast +/- boost: 25 Gy; lymph nodes: 25 Gy",
        "Max # of fractions: whole breast: 28 Gy; breast boost: 10 Gy; tumor bed = whole breast +/- boost: 36 Gy; lymph nodes: 28 Gy",
        "  Min # of sessions: whole breast: 22 Gy; breast boost: 5 Gy; tumor bed = whole breast +/- boost: 25 Gy; lymph nodes: 25 Gy",
        "  Max # of sessions: whole breast: 28 Gy; breast boost: 10 Gy; tumor bed = whole breast +/- boost: 36 Gy; lymph nodes: 28 Gy",
        "  Subjects may or may not have had surgery (lumpectomy or mastectomy) prior to RT; (NOTE: surgery is not required for eligibility)",
        "  Subjects may have had chemotherapy prior to radiation; a minimum of two weeks is required between end of chemotherapy and start of RT",
        "  Subjects may be currently prescribed hormone treatment or Herceptin therapy",
        "  Subjects must be able to read, speak, and understand English",
        "  Subjects must have the ability to understand and the willingness to sign a written informed consent document",
        "  Subjects must agree to not use any other topical agents on skin in the radiation treatment area during the course of this trial; subjects should only use topical agents for the study (i.e., topical intervention or standard care agents) supplied by the study personnel and/or treating physician",
        "Exclusion Criteria:",
        "  Pregnant females are ineligible; all subjects of childbearing potential will be asked if they are pregnant or could be pregnant; the patient must respond \"no\" to continue with radiation and to participate in this clinical study",
        "  Subjects with bilateral breast cancer are not eligible",
        "  Subjects receiving the short-course fractionation radiation therapy (i.e., 16 sessions or 20 sessions at 2.4 to 2.6 Gy fractions per session, with or without boost)",
        "  Subject is currently on anti-EGFR (human epidermal growth factor receptor) therapy, such as Iressa (gefitinib) or Erbitux (cetuximab, C225)",
        "  Previous radiation to the chest or breast",
        "  Subjects with breast reconstruction prior to RT",
        "  Previous diagnosis of radiosensitivity disorder (i.e., ataxia telangiectasia)",
        "  Previous diagnosis of collagen vascular disorder or vasculitis",
        "  Presence of unhealed surgical wounds in chest or breast region and/or breast infection",
        "  Current daily application of a prescribed topical product to the skin within the RT area for an unrelated skin condition that cannot be discontinued during the participation in this clinical trial",
        "  Presence of any active dermatological issues in radiation treatment area (i.e., fungal skin infection, dermatitis, psoriasis plaques, etc)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Mean Radiation Dermatitis Severity (RDS) Score. Range: 0 (no Dermatitis) - 4 (Violaceous Erythema With Diffuse Desquamation Occurring in Sheets; Patchy Crusting; Superficial Ulceration)",
        "  The mean 1 week post-RT RDS score for each arm will be compared using ANOVA to determine if the topical interventions reduce the severity of skin reactions at the end of RT.",
        "  The RDS score ranges from 0-4 with higher scores indicating worse outcome.",
        "  Time frame: Baseline up to 1 week post radiation therapy",
        "Results 1: ",
        "  Arm/Group Title: Arm I (Curcumin-based Gel)",
        "  Arm/Group Description: Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.",
        "Curcumin-based Gel: Applied topically",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Questionnaire Administration: Ancillary studies",
        "  Overall Number of Participants Analyzed: 59",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  2.68         (0.74)",
        "Results 2: ",
        "  Arm/Group Title: Arm II (HPR Plus)",
        "  Arm/Group Description: Patients apply HPR Plus\u2122 topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.",
        "  Dermatologic Complications Management: Apply HPR Plus topically",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Questionnaire Administration: Ancillary studies",
        "  Overall Number of Participants Analyzed: 59",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: units on a scale  2.64         (0.74)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/64 (4.69%)",
        "  Heart Failure * 0/64 (0.00%)",
        "  Radiation Dermatitis * 3/64 (4.69%)",
        "  Headache * 0/64 (0.00%)",
        "  Pleuritic pain * 0/64 (0.00%)",
        "  Dermatitis * 1/64 (1.56%)",
        "Adverse Events 2:",
        "  Total: 2/65 (3.08%)",
        "  Heart Failure * 1/65 (1.54%)",
        "  Radiation Dermatitis * 1/65 (1.54%)",
        "  Headache * 0/65 (0.00%)",
        "  Pleuritic pain * 1/65 (1.54%)",
        "  Dermatitis * 0/65 (0.00%)"
    ]
}